Bedside Talc Pleurodesis for Malignant Pleural Effusion: Factors Affecting Success
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To determine the factors affecting the success of bedside talc slurry (TS) used for symptomatic treatment of patients with malignant pleural effusion (MPE).
Data of 113 effusions in 103 MPE patients treated between 1999 and 2007 were retrospectively evaluated for the study. The study group involved 73 patients whose follow-up information was available out of 81 patients treated by TS. Causes of MPE were lung cancer in 22 patients (30.1%) and breast carcinoma in 21 patients (28.8%).
The success rate of TS was significantly higher if the time period between radiological diagnosis of effusion and administration of TS was less than 30 days (P = .02), or spontaneous expansion was attained after chest tube drainage (CTD) (P = .01). Success rate was higher for patients with daily drainage of less than 200 ml before TS than patients with more than 200 ml of daily drainage (P = .01). Dose of talc, either 4 g or above (P = .34), primary cause of MPE (P = .53), time to termination of CTD (P = .57), amount of drainage when CTD was terminated (P = .23), and time period between CTD and administration of TS (P = .20) did not show a statistically significant effect on the success of TS.
In the treatment of malignant pleural effusion, patients with daily drainage of less than 200 ml before TS developed less recurrence than patients with daily drainage of more than 200 ml. Longer time period between the diagnosis of MPE and onset of CTD increased recurrence.
- Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362–8. CrossRef
- Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(Suppl II):ii29–38.
- Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29:829–38. CrossRef
- Kuzniar TJ, Blum MG, Kasibowska-Kuzniar K, et al. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis. Ann Thorac Surg. 2006;82:1976–81. CrossRef
- Cohen RG, Shely WW, Thompson SE, et al. Talc pleurodesis: Talc slurry versus thoracoscopic talc insufflation in a porcine model. Ann Thorac Surg. 1996;62:1000–2. CrossRef
- Shan SA. Malignant pleural effusions. In: Shields TW, editors. General Thoracic Surgery. 6th ed., vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 935–43.
- Haas RA, Sterman DH, Musani AI. Malignant pleural effusions management options with consideration of coding, billing, and a decision approach. Chest. 2007;132:1036–41. CrossRef
- Ong KC, Indumathi V, Raghuram J, et al. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology. 2000;5:99–103. CrossRef
- Dresler CM, Olak J, Herndon II JE, et al. Phase III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusions. Chest. 2005;127:909–15. CrossRef
- DeCampos JR, Vargas FS, DeCampos Werebe E, et al. Thoracoscopy talc poudrage: a 15-year experience. Chest. 2001;119:801–6. CrossRef
- Kennedy L, Rusch VW, Strange C, et al. Pleurodesis using talc slurry. Chest. 1994;106:342–6. CrossRef
- Stefani A, Natali P, Casali C, et al. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: a prospective comparative study. Eur J Cardiothorac Surg. 2006;30:827–32. CrossRef
- Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusion: an assessment of the prognostic values of physiologic, morphologic and quality of life measures of extent of disease. Chest. 2000;117:73–8. CrossRef
- Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest. 2005;128:1431–5. CrossRef
- Warren WH, Kim AW, Liptay MJ. Identification of clinical factors predicting Pleurx® catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008;33:89–94. CrossRef
- Bedside Talc Pleurodesis for Malignant Pleural Effusion: Factors Affecting Success
Annals of Surgical Oncology
Volume 16, Issue 3 , pp 745-750
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Third Thoracic Surgery, Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery, Istanbul, Turkey